Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plerixafor for Stem Cell Mobilization in Sickle Cell Disease
NCT03664830Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Sep 2018
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of plerixafor in sickle cell disease (SCD), sponsored by City of Hope. Primary endpoint: Toxicities at 120 hours. Started Sep 2018; status: active, not recruiting.
02
Drugs
plerixafor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03664830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664830.